PART I Overview BioVie Inc. (the Company or we or our) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. Neurodegenerative Disease Program The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (NeurMedix) a privately held clinical-stage pharmaceutical company and a related party in June 2021.The acquired assets included NE3107 (or bezisterim). Bezisterim, the approved gener...
Q2 FY2026 — expected 2026-08-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-08-15 | 2025-06-30 | 0001520138-25-000268 | EDGAR | 56K words |
| 2024-09-30 | 2024-06-30 | 0001520138-24-000324 | EDGAR | — |
| 2023-08-16 | 2023-06-30 | 0001520138-23-000325 | EDGAR | — |
| 2022-09-27 | 2022-06-30 | 0001520138-22-000437 | EDGAR | — |
| 2021-08-30 | 2021-06-30 | 0001520138-21-000509 | EDGAR | — |
| 2020-08-06 | 2020-06-30 | 0001520138-20-000356 | EDGAR | — |
| 2019-09-27 | 2019-06-30 | 0001520138-19-000336 | EDGAR | — |
| 2018-10-05 | 2018-06-30 | 0001520138-18-000269 | EDGAR | — |
| 2017-08-24 | 2017-06-30 | 0001520138-17-000286 | EDGAR | — |
| 2016-09-28 | 2016-06-30 | 0001520138-16-001180 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-06 | 2025-12-31 | 0001520138-26-000052 | EDGAR | 20K words |
| 2025-11-10 | 2025-09-30 | 0001520138-25-000343 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001520138-25-000144 | EDGAR | — |
| 2025-02-11 | 2024-12-31 | 0001520138-25-000056 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001520138-24-000425 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001520138-24-000204 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0001520138-24-000069 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001520138-23-000473 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001520138-23-000227 | EDGAR | — |
| 2023-02-10 | 2022-12-31 | 0001520138-23-000087 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0001520138-22-000502 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001520138-22-000201 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001520138-26-000312 | EDGAR | — |
| 2025-11-13 | 0001520138-25-000352 | EDGAR | 1K words |
| 2025-11-12 | 0001520138-25-000347 | EDGAR | — |
| 2025-08-11 | 0001520138-25-000249 | EDGAR | — |
| 2025-07-23 | 0001520138-25-000223 | EDGAR | — |
| 2025-06-27 | 0001520138-25-000190 | EDGAR | — |
| 2025-06-24 | 0001520138-25-000185 | EDGAR | — |
| 2025-03-28 | 0001520138-25-000089 | EDGAR | — |
| 2024-11-08 | 0001520138-24-000410 | EDGAR | — |
| 2024-10-29 | 0001520138-24-000404 | EDGAR | — |
202 total filings indexed. 170 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001580149 |
| Ticker | BIVI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.bioviepharma.com |
| Listed | 2014-01-14 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BIVI (~200 tokens, structured JSON with cryptographic provenance)